Patient Support

A panel of experts examines how stakeholders can support strategies that improve patient outcomes, while also navigating various distribution models.

A survey study takes a closer look into which medications patients would like to have deprescribed, along with the reasons and factors influencing that decision.

The Carlsbad plant is expected to accelerate both the development and commercialization of cell therapies.

Access USA converges in Philadelphia to explore new—and needed—solutions to boost patient outcomes.

A panel discussion uncovers ways to deliver personalized therapy ops in a timely fashion.

The key strategies for reducing or eliminating post-prescription abandonment.

In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Kimberly Westrich, chief strategy officer at the National Pharmaceutical Council, comments on another presentation that has caught her eye at the conference.

A look at the prevailing factors impacting treatment access in 2025.

How pharma manufacturers can steadily navigate GTN components and complexities when planning pharmacy benefit reimbursement.

In the third part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Kimberly Westrich, chief strategy officer at the National Pharmaceutical Council, details the aspect of her presentation that she would have wanted to dive further into.

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Colin Banas, MD, DrFirst’s chief medical officer, shares his thoughts on the rumors that RFK Jr. could potentially ban DTC advertising.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Chris O’Dell, Turquoise Health’s SVP of market solutions, outlines the key provisions of the recently released executive order on healthcare price transparency.

A panel discussion breaks down ways for stakeholders to meet temperature-controlled operational demands pertaining to product pipelines.

In the second part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Rachel Thorpe, executive director at the Otsuka Patient Assistance Foundation, lays out the ways to begin transitioning a foundation.

In the second part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Kimberly Westrich, chief strategy officer at the National Pharmaceutical Council, describes how accumulators, maximizers, and AFPs are impacting patients, manufacturers, and healthcare ecosystems, and how that all ties into the presentation she participated in.

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Colin Banas, MD, DrFirst’s chief medical officer, uncovers the main reasons why 52% of respondents choose DTC online prescription platforms.

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Colin Banas, MD, DrFirst’s chief medical officer, explains the rise in patients turning to DTC platforms following insurance denials.

In the first part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Rachel Thorpe, executive director at the Otsuka Patient Assistance Foundation, describes the various conference sessions that she participated in.

The telehealth company is offering Lilly’s branded form of tirzepatide—approved for weight loss—on its site for $1,899 a month, while Lilly also sells the GLP-1 via its LillyDirect platform.

In the first part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Kimberly Westrich, chief strategy officer at the National Pharmaceutical Council, lays out the basics surrounding accumulators, maximizers, and AFPs.

In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Colin Banas, MD, DrFirst’s chief medical officer, discusses the challenges that many Americans face regarding the affordability of GLP-1 drugs.

Jen Butler, chief commercial officer, Pleio, discusses the importance of balancing technology and personalization in patient support.

Renier Brentjens, MD, PhD outlines the evolution of the space, while offering ways to boost patient access to these treatments.

Jen Butler, chief commercial officer, Pleio, discusses how personalization, connectivity, technology, and proactive support are working to evolve patient engagement strategies.

Jen Butler, chief commercial officer, Pleio, discusses the effectiveness of peer-to-patient outreach when starting specialty medications.